Merck drug Winrevair is the first in a new class of pulmonary arterial hypertension therapies that address a key signaling pathway behind the disease. The drug comes from Merck’s $11.5 billion acquisition of Acceleron Pharma.
The post Merck Drug For Heart And Lung Disorder Wins A First-In-Class FDA Approval appeared first on Above the Law.
from Above the Law https://ift.tt/Iwmv5YA
via IFTTT